Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability.
Saved in:
| Title: | Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability. |
|---|---|
| Authors: | Blauvelt A; Blauvelt Consulting, LLC, Annapolis, MD, USA., Bagel J; Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA., Pinter A; Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Zhou M; Amgen Inc., Thousand Oaks, CA, USA., Cao J; Amgen Inc., Thousand Oaks, CA, USA., Mytych DT; Amgen Inc., Thousand Oaks, CA, USA., Chow V; Amgen Inc., Thousand Oaks, CA, USA., Franklin J; Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | The British journal of dermatology [Br J Dermatol] 2026 May 29. Date of Electronic Publication: 2026 May 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
